Clinical Trials
33 trialsNCT04392960 2026-04-16
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase NA Completed
NCT03201965 2025-11-26
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
Phase 3 Completed
NCT01864018 2025-07-24
Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
Mayo Clinic
Phase 1/2 Completed
NCT02924272 2025-03-12
Ixazomib Rollover Study
Takeda
Phase 2 Completed
NCT05260203 2024-11-06
MargheRITA
Advice Pharma Group srl
Phase NA Completed
NCT05199337 2024-09-19
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT03959358 2023-07-24
A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders
University Health Network, Toronto
Phase 2 Completed
NCT00224393 2023-05-30
Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis
The Cleveland Clinic
Phase 2 Completed
NCT02158052 2022-12-13
Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
Massachusetts General Hospital
Phase NA Completed
NCT03678259 2022-03-25
124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis
University of Tennessee Graduate School of Medicine
Phase 1/2 Completed
NCT01078454 2022-02-01
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
National Cancer Institute (NCI)
Phase 3 Completed
NCT02207556 2021-07-09
DUAL
Medical College of Wisconsin
Phase 2 Completed
NCT00981708 2021-04-30
Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)
University of Athens
Phase 1/2 Completed
NCT02545907 2021-04-15
CATALYST
University College, London
Phase 1/2 Completed
NCT01083316 2020-09-25
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
Boston Medical Center
Phase 2 Completed
NCT01383759 2020-04-07
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT01222260 2020-03-30
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
Columbia University
Phase 2 Completed
NCT01447914 2019-08-28
Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT03779815 2019-04-18
PET
Ulsan University Hospital
Phase NA Completed
NCT02632786 2019-04-05
PRONTO
Prothena Biosciences Ltd.
Phase 2 Completed
NCT01777243 2018-07-24
A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis
GlaxoSmithKline
Phase 1 Completed
NCT00952237 2018-04-25
Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF
Dartmouth-Hitchcock Medical Center
Phase 1 Completed
NCT02791373 2018-04-03
ViGeM
Insel Gruppe AG, University Hospital Bern
Phase 2 Completed
NCT01677286 2017-08-01
Safety and Effect of Doxycycline in Patients With Amyloidosis
Boston University
Phase 2 Completed
NCT01406314 2017-06-09
SAP Depleter Dose Assessment Study in Patients
GlaxoSmithKline
Phase 1 Completed
NCT01194791 2017-04-25
LENDEXAL
PETHEMA Foundation
Phase 2 Completed
NCT00890552 2017-03-22
A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
Stanford University
Phase NA Completed
NCT01277016 2017-03-10
EMN-03
European Myeloma Network B.V.
Phase 3 Completed
NCT02953808 2017-01-19
Phase 1 Study of GSK2315698 in Healthy Japanese Subjects
GlaxoSmithKline
Phase 1 Completed
NCT01998503 2013-11-29
Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis
Nanjing University School of Medicine
Phase 3 Completed
NCT00621400 2011-05-10
Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis
Nantes University Hospital
Phase 1/2 Completed
NCT00017680 2008-06-09
Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis
Office of Rare Diseases (ORD)
Phase 2 Completed
NCT00035334 2006-02-14
Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
Bellus Health Inc. - a GSK company
Phase 2/3 Completed